North Carolina Headlines

DelveInsight’s Metastatic Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of Metastatic Prostate Cancer, historical and forecasted epidemiology, and market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

To read more about the latest highlights related to the Metastatic Prostate Cancer Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/report-store/metastatic-prostate-cancer-market

Key Takeaways from the Metastatic Prostate Cancer Market Report

• In March 2026, the Prostate Cancer Foundation introduced the Hastens-PCF Global Health Award to improve equitable access to prostate cancer detection, diagnosis, and treatment in emerging countries and to help expand the STAMPEDE2 clinical trial in Nigeria.

• In December 2025, Telix Pharmaceuticals announced that the first patient has been dosed in Part 2 of its ProstACT Global Phase III study evaluating TLX591, its lead prostate cancer therapy candidate, in patients with metastatic castration-resistant prostate cancer (mCRPC).

• The Metastatic Prostate Cancer Market Size was approximately USD 11,500 million across the 7MM (the US, EU4, the UK, and Japan) in 2025, and is projected to grow at a significant CAGR during the forecast period from 2026 to 2036.

• The United States remains the largest Metastatic Prostate Cancer market, accounting for the highest revenue share in 2025, driven by high disease prevalence, strong uptake of novel therapies, advanced diagnostic infrastructure including PSMA PET/CT, and favorable reimbursement compared with EU4, the UK, and Japan.

• According to DelveInsight’s estimates, the total number of prevalent cases of metastatic prostate cancer in the 7MM were approximately 315,000 in 2025, with the US alone accounting for approximately 3,864,000 prevalent cases of prostate cancer overall.

• Leading Metastatic Prostate Cancer companies include Curium, Bristol-Myers Squibb, Merck and Orion, Pfizer, Merus, Zenith Epigenetics, AstraZeneca, Telix International, Novartis, Eli Lilly/POINT Biopharma, and others.

• Leading Metastatic Prostate Cancer Therapies includeApalutamide (ERLEADA), Enzalutamide (XTANDI), Darolutamide (NUBEQA), Cabazitaxel (JEVTANA), Abiraterone acetate (ZYTIGA), Lutetium vipivotide tetraxetan (PLUVICTO), Olaparib (LYNPARZA), Talazoparib (TALZENNA), TLX591, Mevrometostat (PF-06821497), Cabozantinib (CABOMETYX), and others.

To know more about why the United States is leading the market growth in the Metastatic Prostate Cancer Market, get a snapshot @ Metastatic Prostate Cancer Market Outlook

Metastatic Prostate Cancer Market Dynamics

The Metastatic Prostate Cancer therapeutics market is undergoing a major transition from conventional androgen deprivation therapy (ADT) toward combination-based, biomarker-driven, and precision-targeted treatment approaches. Metastatic prostate cancer is an advanced stage of prostate malignancy in which cancer cells spread beyond the prostate gland to distant sites — most commonly the bone, lymph nodes, liver, and lungs — progressing from localized disease through metastatic hormone-sensitive prostate cancer (mHSPC) and eventually to metastatic castration-resistant prostate cancer (mCRPC). The disease is diagnosed using a combination of PSA testing, bone scans, CT/MRI, PSMA PET/CT, and histopathological confirmation. While AR pathway inhibitors including enzalutamide (XTANDI), apalutamide (ERLEADA), darolutamide (NUBEQA), and abiraterone acetate (ZYTIGA) continue to dominate across mHSPC and mCRPC settings, the emergence of PARP inhibitors for HRR/BRCA-mutated disease and PSMA-targeted radioligand therapies such as Lu-177–PSMA-617 (PLUVICTO) is significantly reshaping the treatment paradigm. The rapidly ageing global population, rising prevalence of prostate cancer, expanding label approvals, integration of molecular testing and PSMA imaging, and a robust late-stage pipeline comprising next-generation PARP inhibitors, AKT inhibitors, PSMA-targeted agents, and novel AR degraders are collectively driving sustained market expansion through 2036.

Metastatic Prostate Cancer Market Segmentation Analysis

Metastatic Prostate Cancer Market by Disease Type (Metastatic Hormone-Sensitive Prostate Cancer — mHSPC/mCSPC, and Metastatic Castration-Resistant Prostate Cancer — mCRPC), Metastatic Prostate Cancer Market by Drug Class (Androgen Receptor Pathway Inhibitors — ARPIs, Androgen Deprivation Therapy — ADT, Chemotherapy, PARP Inhibitors, Radioligand Therapies, Immunotherapy, and Targeted Therapies), Metastatic Prostate Cancer Market by Biomarker Status (HRR/BRCA-Mutated, PSMA-Positive, MSI-High/dMMR, and Unselected), Metastatic Prostate Cancer Market by Line of Therapy (First-Line, Second-Line, and Later Lines), and Metastatic Prostate Cancer Market by Geography (North America — US; Europe — Germany, France, Italy, Spain, UK; Asia-Pacific — Japan)

Get a sneak peek at the Metastatic Prostate Cancer Market Dynamics @ Metastatic Prostate Cancer Market Dynamics Analysis

Metastatic Prostate Cancer Companies

Curium, Bristol-Myers Squibb, Merck and Orion, Pfizer, Merus, Zenith Epigenetics, AstraZeneca, Telix International, Novartis, Eli Lilly/POINT Biopharma, Johnson & Johnson, Astellas Pharma, Exelixis, Ipsen Pharma, Takeda, Xencor, ORIC Pharmaceuticals, Blue Earth Therapeutics, Promontory Therapeutics, and others.

Metastatic Prostate Cancer Market Drivers

The Metastatic Prostate Cancer Market is poised for significant growth, driven by the high and rising global burden of prostate cancer — particularly in the rapidly ageing population — and the substantial progression of patients to advanced metastatic stages where unmet need remains greatest. The expanding adoption of treatment intensification strategies combining ADT with ARPIs and chemotherapy, supported by pivotal trials including TITAN, ARCHES, ARASENS, and PEACE-1, is improving survival outcomes and driving earlier use of combination regimens. The establishment of theragnostics as a new treatment pillar through PLUVICTO, rapid growth in genomically targeted PARP inhibitor therapies for HRR/BRCA-mutated mCRPC, increasing integration of PSMA PET imaging and molecular biomarker testing, and a robust late-stage pipeline including next-generation radioligand therapies, EZH2 inhibitors, and novel AR degraders are further accelerating market expansion. Favorable reimbursement in the US, evolving treatment guidelines, and growing precision oncology adoption across the 7MM collectively position the Metastatic Prostate Cancer Market for strong growth from 2026 to 2036.

Which key players in the Metastatic Prostate Cancer Market are set to emerge as trendsetters? Explore @ Metastatic Prostate Cancer Companies

Scope of the Metastatic Prostate Cancer Market Report

• Coverage: 7MM

• Study Period: 2022–2036

• Forecast Period: 2026–2036

• Metastatic Prostate Cancer Companies: Curium, Bristol-Myers Squibb, Merck and Orion, Pfizer, Merus, Zenith Epigenetics, AstraZeneca, Telix International, Novartis, Eli Lilly/POINT Biopharma, and others.

• Metastatic Prostate Cancer Therapies: Apalutamide (ERLEADA), Enzalutamide (XTANDI), Darolutamide (NUBEQA), Cabazitaxel (JEVTANA), Abiraterone acetate (ZYTIGA), Lutetium vipivotide tetraxetan (PLUVICTO), Olaparib (LYNPARZA), Talazoparib (TALZENNA), TLX591, Mevrometostat (PF-06821497), Cabozantinib (CABOMETYX), and others.

• Key Analysis: Total Market Size, Market Size by Therapies and Drug Class, Epidemiology Segmentation, Pipeline Analysis (Phase I–III), Drug Uptake, Reimbursement, SWOT and Conjoint Analysis, KOL Views

Interested in knowing the Metastatic Prostate Cancer Market outlook through 2036? Click to get a snapshot of the Metastatic Prostate Cancer Market Trends

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Metastatic Prostate Cancer

4. Key Events

5. Epidemiology and Market Forecast Methodology

6. Prostate Cancer Market Overview at a Glance

7. Disease Background and Overview

8. Epidemiology and Patient Population

9. Patient Journey

10. Marketed Drugs

11. Additional Marketed Therapies

12. Emerging Drugs

13. Metastatic Prostate Cancer: 7MM Analysis

14. Unmet Needs

15. SWOT Analysis

16. KOL Views

17. Market Access and Reimbursement

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/metastatic-prostate-cancer-market